Ed Silverman is a senior writer and Pharmalot columnist at STAT. With over three decades of experience, he specializes in the pharmaceutical industry, covering themes such as pharmaceutical regulation, healthcare administration, and public health. Ed's work has been featured in prominent publications including The Boston Globe, Njarts.net, and Environmental Health News.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
United States (National)
Not enough data
Ed Silverman's articles predominantly revolve around the healthcare and pharmaceutical industry, with a specific focus on government announcements, legal policy regulations, and data citations. His coverage suggests he would be most receptive to pitches offering insights into regulatory developments impacting the pharmaceutical industry.
Given his coverage of comings and goings within the industry, Ed may also be interested in news relating to executive appointments or departures at prominent pharmaceutical companies.
As there is no specified geographic focus for Ed's work, it is advisable to provide information relevant to global trends or developments within the healthcare and pharmaceutical sector.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Ed Silverman
Drugmaker was ‘likely to be significantly harmed' by the payment limit placed on Enbrel
By: Ed Silverman
In a victory for the pharmaceutical industry, a U.S. judge blocked a Colorado state panel from placing a cap on the price of Amgen's blockbuster drug Enbrel after deciding the company is “likely to be significantly harmed,”
Hired someone new and exciting? Promoted a rising star? Finally solved that hard-to-fill spot? Share the news with us, and we'll share it with others.
By: Ed Silverman
The drug maker stopped offering discounts last month to reduce what it calls duplicate discounts paid to the hospitals
By: Ed Silverman, Jul By
France's ANSM fined Novo Nordisk and Eli Lilly over obesity “awareness” campaigns it says crossed into banned direct-to-consumer promotion. With probes opening across Europe and fines dwarfed by drug revenue, the test is whether enforcement can keep pace with the gold rush.
By: Ed Silverman
Value of China's innovative drug out-licensing deals reached about $110 billion in first half of 2026
By: Ed Silverman
Advocacy group contends the company was rewarded for infringing on government-held patents
By: Ed Silverman
A large trial will explore whether lifestyle changes and GLP-1 drugs reduce dementia risk Rise and shine, everyone, another busy day is on the way.
By: Ed Silverman
Prescription medicines purchased in the U.S. under a controversial government discount program amounted to $100 billion in 2025, a 22.8% increase from the previous year, according to the U.S. Health Resources & Services Administration, which oversees the program.
By: Ed Silverman
The Federal Trade Commission settled a lawsuit against CVS Caremark, one of the largest pharmacy benefit managers in the U.S., over allegations that the company artificially inflated the price of insulin and impeded access to the lifesaving diabetes treatment.
